Session leader & speaker
Developing, manufacturing and commercializing advanced therapies
Led a special session examining the development and industrialization of autologous and allogeneic products—and the strategic trade-offs between them.
Speaking · Conferences · Professional societies
Speaking & conferences.
Selected invited talks, oral presentations, conference contributions and topics across advanced therapies, translational development and the decisions that connect science with strategy.
15+International abstracts & presentations since 2020
Featured speaking
Selected platforms and presentations.
First & presenting author · Oral
Standardizing MSC therapies
Presented a framework for addressing donor variability and benchmarking functional heterogeneity in mesenchymal stromal cell development.
Invited oral presentation
BonoFill and living bone regeneration
Invited to present the translational development of an autologous tissue-engineered bone graft in Fort Lauderdale, Florida.
Plenary Best Papers · Oral
MesenCure from research toward clinical use
Presented MesenCure in the plenary Best Papers session and received the meeting’s Best Paper Award.
Selected conference record
Roles made explicit.
Invited talks, presenting-author contributions and co-authored work are identified separately to keep the record precise.
2025
First authorPresenting author
Standardizing MSC therapies: A framework for addressing donor variability and benchmarking functional heterogeneity
Cytotherapy 27(5 Suppl):S9.
Co-author
Engineering people to engineer cells: An agile HR framework for advancing cell and gene therapies
Cytotherapy 27(5 Suppl):S136.
2024
Presenting author
Advancing mesenchymal cell-based bone tissue engineering: Comprehensive Phase II clinical trial outcomes of BonoFill in maxillofacial reconstruction
Cytotherapy 26(6 Suppl):S20–S21.
Session leaderSpeaker
Development, industrial manufacturing and commercialization of autologous and allogeneic advanced therapies
2023
Co-author
Complicated large maxillofacial bone deficiencies successfully reconstructed using BonoFill
International Journal of Oral and Maxillofacial Surgery 52(Suppl):12–13 (published 2024).
Co-author
Biological threat agent ricin intoxication of the lungs is effectively treated by MesenCure
Cytotherapy 25(6 Suppl):S89–S90.
Co-author
Mesenchymal-based hyper-vasculogenic bone graft enhances vascularization, bone formation and integration
Cytotherapy 25(6 Suppl):S138–S139.
Presenter
Advanced cell-therapy development
Showcase presentation; no meeting abstract.
2022
Invited speakerCo-author
BonoFill conference presentation in Fort Lauderdale, Florida
First authorPresenting author
MesenCure: A professionalized cell therapy for ARDS reduced mortality in a multi-center, controlled Phase II study
Cytotherapy 24(5 Suppl):S31.
Presenting author
Translational potential of MesenCure for immunotherapy-related cytokine release syndrome
Cytotherapy 24(5 Suppl):S24–S25.
Co-author
BonoFill: A tissue-engineered autologous bone graft from adipose-derived mesenchymal stromal cells
Cytotherapy 24(5 Suppl):S46.
2021
First authorPresenting author
MesenCure—an enhanced cell therapy for acute respiratory distress in COVID-19: From benchtop to bedside
Cytotherapy 23(5 Suppl):S21.
First author
Divergent local and peripheral immunological effects of low-dose MesenCure in severe COVID-19
Blood 138(Suppl):2172.
PresenterBest Paper Award
MesenCure cell-therapy development
2020
Co-author
BonoFill-II, from bench to bedside: A cell-based, tissue-engineered product for large segmental bone defects
Cytotherapy 22(5 Suppl):S20.
Speaking themes
Where science meets the decisions around it.
From bench to boardroom
How scientific evidence changes when it must support development, partnerships, financing and executive decisions.
Evaluating advanced-therapy opportunities
A practical framework connecting mechanism, translation, manufacturing, regulation, clinical design, market potential and value.
Autologous & allogeneic therapies
The development, manufacturing, access and commercialization trade-offs between patient-specific and donor-derived products.
Scientific evidence & capital strategy
Why clinical milestones, manufacturing readiness, market assumptions and financing requirements must form one coherent system.
Academic innovation to venture translation
Lessons from moving science across intellectual property, diligence, technology transfer and venture formation.
Standardizing cell therapies
Donor variability, functional heterogeneity, potency and the evidence frameworks required for reproducible development.
Speaking invitations